Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 40.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 324,064 shares of the company's stock after purchasing an additional 92,985 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.45% of Kiniksa Pharmaceuticals worth $8,098,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Essex Investment Management Co. LLC lifted its holdings in shares of Kiniksa Pharmaceuticals by 0.4% during the 3rd quarter. Essex Investment Management Co. LLC now owns 200,516 shares of the company's stock valued at $5,011,000 after purchasing an additional 717 shares during the last quarter. Linden Thomas Advisory Services LLC raised its stake in Kiniksa Pharmaceuticals by 1.7% in the second quarter. Linden Thomas Advisory Services LLC now owns 118,302 shares of the company's stock valued at $2,209,000 after buying an additional 1,921 shares during the last quarter. CWM LLC boosted its holdings in Kiniksa Pharmaceuticals by 443.0% in the third quarter. CWM LLC now owns 2,449 shares of the company's stock worth $61,000 after acquiring an additional 1,998 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Kiniksa Pharmaceuticals by 2.3% in the second quarter. Bank of New York Mellon Corp now owns 115,143 shares of the company's stock worth $2,150,000 after acquiring an additional 2,563 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Kiniksa Pharmaceuticals by 65.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company's stock valued at $195,000 after acquiring an additional 3,076 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ:KNSA traded up $0.19 during midday trading on Friday, reaching $21.28. 191,939 shares of the company's stock traded hands, compared to its average volume of 365,613. The company has a market cap of $1.54 billion, a P/E ratio of -152.00 and a beta of 0.35. Kiniksa Pharmaceuticals, Ltd. has a 1 year low of $15.52 and a 1 year high of $28.15. The company has a fifty day simple moving average of $24.29 and a two-hundred day simple moving average of $22.88.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. During the same quarter in the previous year, the firm posted ($0.20) earnings per share. The business's revenue was up 67.4% compared to the same quarter last year. As a group, research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Analysts Set New Price Targets

KNSA has been the subject of a number of recent research reports. Evercore ISI lifted their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Jefferies Financial Group initiated coverage on Kiniksa Pharmaceuticals in a report on Friday, September 13th. They set a "buy" rating and a $40.00 target price on the stock. Finally, JPMorgan Chase & Co. boosted their price target on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an "overweight" rating in a report on Tuesday, November 5th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals has an average rating of "Buy" and a consensus target price of $36.60.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 17,500 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $26.91, for a total transaction of $470,925.00. Following the completion of the transaction, the chief operating officer now directly owns 119,911 shares in the company, valued at approximately $3,226,805.01. This represents a 12.74 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John F. Paolini sold 60,692 shares of the firm's stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the sale, the insider now directly owns 52,038 shares of the company's stock, valued at $1,359,232.56. The trade was a 53.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 112,692 shares of company stock worth $2,950,315 in the last ninety days. 54.57% of the stock is owned by insiders.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.